ABSTRACT NUMBER: ESOC2026LT15 LT15 - SAFETY AND EFFICACY OF RECOMBINANT HUMAN DNASE1 (DORNASE ALFA) AS AN ADJUVANT THROMBOLYTIC IN LARGE VESSEL ISCHAEMIC STROKE: THE EXTEND-IA DNASE CLINICAL TRIAL
Bruce Campbell, Vignan Yogendrakumar, Leonid Churilov, Hannah Johns, Chloe Mutimer, Valerian Altersberger, Gagan Jyoti Sharma, Philip Choi, Vincent Thijs, Timothy Kleinig · 2026
Read ABSTRACT NUMBER: ESOC2026LT15 LT15 - SAFETY AND EFFICACY OF RECOMBINANT HUMAN DNASE1 (DORNASE ALFA) AS AN ADJUVANT THROMBOLYTIC IN LARGE VESSEL ISCHAEMIC STROKE: THE EXTEND-IA DNASE CLINICAL TRIAL by Bruce Campbell, Vignan Yogendrakumar, Leonid Churilov, Hannah Johns, Chloe Mutimer, Valerian Altersberger, Gagan Jyoti Sharma, Philip Choi, Vincent Thijs, Timothy Kleinig (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146526.txt.
Description
Bruce Campbell and co-authors report a dose finding trial of a clot aiding enzyme in stroke care in a 2026 conference abstract. Standard clot busting drugs reopen blocked brain arteries too rarely. The enzyme dornase alfa digests DNA webs inside clots, which speeds breakdown in the lab without touching normal clotting.
Over three years, three hundred thirty patients at seventeen Australian sites got standard drug care plus one of four rising enzyme doses. The trial's main goal was early artery reopening without brain bleeding. Full outcome results were still pending at the time of the abstract, set for release at the 2026 conference. The design used running futility checks to drop weak doses early.
Catalog record
| CREATOR | Bruce Campbell, Vignan Yogendrakumar, Leonid Churilov, Hannah Johns, Chloe Mutimer, Valerian Altersberger, Gagan Jyoti Sharma, Philip Choi, Vincent Thijs, Timothy Kleinig |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |